arrow
C

Christos Tziotzios

St Johns Institute of Dermatology
H指数:19
被引数:2,008

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

更正:来自ALLEGRO临床试验方案的口服JAK3/TEC家族激酶抑制剂利特昔替尼治疗斑秃的综合安全性分析

2026-09-250
OAAI
Genome-wide meta-analysis in lichen sclerosus identifies 14 genomic risk loci

全身性硬皮病的全基因组荟萃分析确定了14个基因组风险位点

2026-05-011
PRE
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

更正:来自ALLEGRO临床研究项目的口服JAK3/TEC家族激酶抑制剂Ritlecitinib治疗斑秃的综合安全性分析

2025-09-110
OAAI
Characterization of the clinical and photobiologic features of solar urticaria: a UK multicentre cross-sectional study

太阳能荨麻疹的临床和光生物学特征表征:一项英国多中心横断面研究

2025-08-010
OAAI
Psychosocial burden and the impact of illness perceptions and stigma on quality of life, anxiety and depression in alopecia areata: results from the Alopecia plus Me study

斑秃患者的社会心理负担以及疾病认知和污名化对生活质量、焦虑和抑郁的影响:Alopecia + Me研究的结果

2025-07-013
OA
Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study

利特昔替尼在成人及青少年斑秃患者(头皮毛发损失至少25%)中的长期安全性与有效性:ALLEGRO-LT III期开放标签研究结果

2025-01-230
OAAI
Characterization of demographic, clinical and photobiological features of solar urticaria: a UK multicentre cross-sectional study
2024-06-280
OA
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program (vol 25, pg 299, 2024)
2024-05-240
OAAI
Shared Genetic Risk Variants in Both Male and Female Frontal Fibrosing Alopecia

男性和女性额叶纤维脱发的共同遗传风险变异

2023-11-014
OAAI